| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain, Postoperative | 43 | 2023 | 269 | 7.780 |
Why?
|
| Analgesics, Opioid | 35 | 2023 | 209 | 6.410 |
Why?
|
| Pain Management | 23 | 2021 | 125 | 4.580 |
Why?
|
| Analgesics | 25 | 2023 | 78 | 4.100 |
Why?
|
| Chronic Pain | 27 | 2023 | 124 | 3.630 |
Why?
|
| Low Back Pain | 25 | 2021 | 128 | 3.420 |
Why?
|
| Pain Measurement | 44 | 2020 | 411 | 3.230 |
Why?
|
| Morphine | 21 | 2021 | 69 | 2.940 |
Why?
|
| Analgesia | 11 | 2021 | 32 | 2.880 |
Why?
|
| Arthroplasty, Replacement, Knee | 14 | 2021 | 556 | 2.540 |
Why?
|
| Complex Regional Pain Syndromes | 8 | 2020 | 20 | 2.450 |
Why?
|
| Nerve Block | 13 | 2020 | 61 | 2.220 |
Why?
|
| Opioid-Related Disorders | 5 | 2021 | 57 | 2.060 |
Why?
|
| Disease Models, Animal | 12 | 2022 | 512 | 2.040 |
Why?
|
| Anesthetics, Local | 11 | 2016 | 71 | 1.930 |
Why?
|
| Humans | 118 | 2023 | 22592 | 1.810 |
Why?
|
| gamma-Aminobutyric Acid | 11 | 2012 | 25 | 1.730 |
Why?
|
| Anesthesia, Conduction | 12 | 2021 | 30 | 1.710 |
Why?
|
| Spinal Cord Stimulation | 6 | 2022 | 13 | 1.590 |
Why?
|
| Dexamethasone | 5 | 2016 | 34 | 1.580 |
Why?
|
| Cyclooxygenase Inhibitors | 9 | 2016 | 24 | 1.560 |
Why?
|
| Ketamine | 6 | 2019 | 23 | 1.560 |
Why?
|
| Bupivacaine | 5 | 2016 | 39 | 1.530 |
Why?
|
| Acute Pain | 6 | 2023 | 22 | 1.370 |
Why?
|
| Arthroplasty, Replacement, Hip | 9 | 2017 | 684 | 1.350 |
Why?
|
| Pain | 12 | 2021 | 325 | 1.330 |
Why?
|
| Female | 67 | 2022 | 12734 | 1.310 |
Why?
|
| Male | 75 | 2022 | 12260 | 1.310 |
Why?
|
| Surgical Wound Infection | 4 | 2018 | 76 | 1.230 |
Why?
|
| Animals | 31 | 2022 | 3238 | 1.160 |
Why?
|
| Middle Aged | 49 | 2021 | 7800 | 1.120 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2016 | 68 | 1.120 |
Why?
|
| Motor Activity | 7 | 2017 | 267 | 1.110 |
Why?
|
| Ketorolac | 4 | 2016 | 12 | 1.100 |
Why?
|
| Pain Threshold | 8 | 2021 | 25 | 0.950 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 10 | 2010 | 22 | 0.950 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2018 | 39 | 0.940 |
Why?
|
| Zygapophyseal Joint | 5 | 2020 | 27 | 0.920 |
Why?
|
| Inflammation Mediators | 3 | 2017 | 58 | 0.920 |
Why?
|
| Adult | 39 | 2021 | 6826 | 0.910 |
Why?
|
| Rats, Sprague-Dawley | 21 | 2018 | 312 | 0.890 |
Why?
|
| Electric Stimulation Therapy | 7 | 2022 | 39 | 0.880 |
Why?
|
| Analgesia, Epidural | 7 | 2017 | 54 | 0.880 |
Why?
|
| Anesthesia, Epidural | 4 | 2015 | 18 | 0.830 |
Why?
|
| Spouses | 7 | 2019 | 30 | 0.820 |
Why?
|
| Analgesia, Patient-Controlled | 5 | 2017 | 20 | 0.820 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2021 | 289 | 0.820 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2022 | 11 | 0.820 |
Why?
|
| Lumbar Vertebrae | 5 | 2021 | 353 | 0.810 |
Why?
|
| Spine | 4 | 2021 | 95 | 0.790 |
Why?
|
| Cytokines | 4 | 2015 | 200 | 0.770 |
Why?
|
| Prospective Studies | 13 | 2021 | 1476 | 0.760 |
Why?
|
| Glucocorticoids | 4 | 2020 | 58 | 0.760 |
Why?
|
| Arthralgia | 4 | 2020 | 95 | 0.760 |
Why?
|
| Sciatic Nerve | 5 | 2016 | 21 | 0.750 |
Why?
|
| Anger | 3 | 2017 | 32 | 0.740 |
Why?
|
| Clonidine | 6 | 2016 | 17 | 0.730 |
Why?
|
| Double-Blind Method | 18 | 2023 | 371 | 0.730 |
Why?
|
| Aged | 27 | 2021 | 7300 | 0.720 |
Why?
|
| Lactones | 3 | 2007 | 9 | 0.720 |
Why?
|
| Treatment Outcome | 19 | 2021 | 2915 | 0.710 |
Why?
|
| Neuralgia | 3 | 2019 | 9 | 0.700 |
Why?
|
| Mice | 8 | 2022 | 1224 | 0.690 |
Why?
|
| Electrodes, Implanted | 5 | 2018 | 20 | 0.690 |
Why?
|
| Anesthesia, Obstetrical | 2 | 2015 | 10 | 0.680 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 7 | 2020 | 86 | 0.670 |
Why?
|
| Abdominal Muscles | 1 | 2020 | 6 | 0.640 |
Why?
|
| Osteoarthritis, Knee | 2 | 2021 | 292 | 0.640 |
Why?
|
| Edema | 1 | 2020 | 21 | 0.640 |
Why?
|
| Metformin | 1 | 2020 | 15 | 0.640 |
Why?
|
| Program Evaluation | 1 | 2020 | 102 | 0.640 |
Why?
|
| Antiemetics | 1 | 2020 | 10 | 0.640 |
Why?
|
| Sulfones | 4 | 2010 | 20 | 0.640 |
Why?
|
| Central Nervous System | 3 | 2010 | 48 | 0.640 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 28 | 0.640 |
Why?
|
| Hyperalgesia | 6 | 2022 | 44 | 0.620 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 51 | 0.600 |
Why?
|
| Catastrophization | 5 | 2021 | 23 | 0.590 |
Why?
|
| Interpersonal Relations | 6 | 2019 | 86 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 5 | 2022 | 354 | 0.580 |
Why?
|
| Societies, Medical | 7 | 2020 | 117 | 0.580 |
Why?
|
| Anesthesia | 2 | 2010 | 28 | 0.580 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 356 | 0.580 |
Why?
|
| Vancomycin | 1 | 2018 | 52 | 0.570 |
Why?
|
| Spinal Fusion | 4 | 2021 | 429 | 0.560 |
Why?
|
| Ultrasonography, Interventional | 3 | 2019 | 60 | 0.540 |
Why?
|
| Injections, Spinal | 6 | 2019 | 32 | 0.540 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2012 | 22 | 0.530 |
Why?
|
| Laparotomy | 2 | 2016 | 16 | 0.530 |
Why?
|
| Anticoagulants | 6 | 2018 | 83 | 0.530 |
Why?
|
| Administration, Intravenous | 2 | 2017 | 22 | 0.520 |
Why?
|
| Cyclohexanecarboxylic Acids | 4 | 2012 | 7 | 0.520 |
Why?
|
| Amines | 4 | 2012 | 8 | 0.520 |
Why?
|
| Buprenorphine | 1 | 2016 | 3 | 0.510 |
Why?
|
| Cervical Vertebrae | 3 | 2016 | 271 | 0.510 |
Why?
|
| Pregabalin | 8 | 2012 | 14 | 0.500 |
Why?
|
| Rats | 17 | 2022 | 625 | 0.490 |
Why?
|
| Equipment Failure | 1 | 2016 | 34 | 0.490 |
Why?
|
| Epidural Space | 3 | 2015 | 19 | 0.490 |
Why?
|
| Time Factors | 11 | 2018 | 1247 | 0.490 |
Why?
|
| International Cooperation | 1 | 2015 | 14 | 0.480 |
Why?
|
| Spinal Cord | 5 | 2012 | 73 | 0.480 |
Why?
|
| Joints | 1 | 2016 | 66 | 0.480 |
Why?
|
| Health Surveys | 1 | 2015 | 73 | 0.470 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 228 | 0.470 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 800 | 0.460 |
Why?
|
| Random Allocation | 4 | 2020 | 101 | 0.460 |
Why?
|
| Platelet Function Tests | 1 | 2015 | 2 | 0.460 |
Why?
|
| Ticlopidine | 1 | 2015 | 5 | 0.460 |
Why?
|
| Patient Satisfaction | 3 | 2017 | 255 | 0.460 |
Why?
|
| Medication Errors | 1 | 2015 | 12 | 0.460 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2014 | 7 | 0.450 |
Why?
|
| Acetaminophen | 4 | 2023 | 22 | 0.450 |
Why?
|
| Steroids | 1 | 2014 | 22 | 0.450 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 46 | 0.440 |
Why?
|
| Dinoprostone | 4 | 2007 | 16 | 0.440 |
Why?
|
| Consensus | 8 | 2022 | 81 | 0.440 |
Why?
|
| General Surgery | 1 | 2015 | 50 | 0.440 |
Why?
|
| Infection Control | 1 | 2015 | 168 | 0.440 |
Why?
|
| Hematoma, Epidural, Spinal | 1 | 2014 | 3 | 0.430 |
Why?
|
| Young Adult | 9 | 2018 | 1607 | 0.420 |
Why?
|
| Models, Animal | 2 | 2016 | 98 | 0.410 |
Why?
|
| Aspirin | 1 | 2014 | 48 | 0.400 |
Why?
|
| Postoperative Complications | 3 | 2021 | 804 | 0.400 |
Why?
|
| Cohort Studies | 5 | 2021 | 1386 | 0.400 |
Why?
|
| Fentanyl | 2 | 2003 | 24 | 0.400 |
Why?
|
| Length of Stay | 4 | 2021 | 293 | 0.390 |
Why?
|
| Chronic Disease | 7 | 2010 | 373 | 0.390 |
Why?
|
| Magnesium | 2 | 2003 | 35 | 0.390 |
Why?
|
| Catheter Ablation | 3 | 2018 | 33 | 0.390 |
Why?
|
| Naloxone | 6 | 2019 | 13 | 0.390 |
Why?
|
| Evidence-Based Medicine | 6 | 2018 | 135 | 0.370 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 35 | 0.370 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2011 | 8 | 0.370 |
Why?
|
| Substance P | 1 | 2011 | 10 | 0.370 |
Why?
|
| Brain | 2 | 2010 | 1123 | 0.370 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 151 | 0.370 |
Why?
|
| Norepinephrine | 1 | 2011 | 28 | 0.370 |
Why?
|
| Combined Modality Therapy | 6 | 2018 | 292 | 0.370 |
Why?
|
| Glutamic Acid | 1 | 2011 | 21 | 0.370 |
Why?
|
| United States | 12 | 2021 | 1741 | 0.370 |
Why?
|
| Phantom Limb | 2 | 2008 | 3 | 0.360 |
Why?
|
| Isoenzymes | 4 | 2004 | 50 | 0.360 |
Why?
|
| Hip Joint | 3 | 2012 | 246 | 0.350 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 70 | 0.350 |
Why?
|
| Blood Patch, Epidural | 2 | 2008 | 6 | 0.350 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 10 | 0.340 |
Why?
|
| Injections | 5 | 2020 | 42 | 0.340 |
Why?
|
| Behavior, Animal | 5 | 2016 | 47 | 0.330 |
Why?
|
| Neutrophils | 2 | 2016 | 91 | 0.330 |
Why?
|
| Wound Healing | 1 | 2010 | 108 | 0.330 |
Why?
|
| Brain Mapping | 1 | 2010 | 93 | 0.320 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2011 | 64 | 0.320 |
Why?
|
| Ganglia, Spinal | 2 | 2022 | 52 | 0.320 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2015 | 19 | 0.320 |
Why?
|
| Denervation | 3 | 2020 | 20 | 0.320 |
Why?
|
| Cross-Over Studies | 7 | 2018 | 64 | 0.310 |
Why?
|
| Hostility | 3 | 2018 | 23 | 0.310 |
Why?
|
| Sleep | 3 | 2019 | 267 | 0.310 |
Why?
|
| Drug Delivery Systems | 2 | 2019 | 25 | 0.310 |
Why?
|
| Chicago | 4 | 2015 | 788 | 0.310 |
Why?
|
| Pilot Projects | 3 | 2020 | 369 | 0.300 |
Why?
|
| Hematoma, Subdural, Intracranial | 1 | 2008 | 1 | 0.300 |
Why?
|
| Subdural Effusion | 1 | 2008 | 6 | 0.300 |
Why?
|
| Opioid Peptides | 4 | 2020 | 10 | 0.300 |
Why?
|
| Memantine | 1 | 2008 | 7 | 0.300 |
Why?
|
| Anesthesiologists | 2 | 2018 | 6 | 0.290 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 229 | 0.280 |
Why?
|
| Administration, Oral | 3 | 2018 | 98 | 0.280 |
Why?
|
| Physicians, Family | 1 | 2008 | 4 | 0.280 |
Why?
|
| Specialization | 1 | 2008 | 11 | 0.280 |
Why?
|
| Neoplasms | 1 | 2010 | 216 | 0.280 |
Why?
|
| Decompression, Surgical | 2 | 2021 | 117 | 0.270 |
Why?
|
| Cyclooxygenase 2 | 6 | 2008 | 29 | 0.270 |
Why?
|
| Risk Factors | 6 | 2018 | 1955 | 0.270 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 32 | 0.270 |
Why?
|
| Referral and Consultation | 1 | 2008 | 78 | 0.270 |
Why?
|
| Diclofenac | 1 | 2007 | 3 | 0.270 |
Why?
|
| Preoperative Care | 1 | 2007 | 104 | 0.260 |
Why?
|
| Drug Combinations | 2 | 2016 | 31 | 0.260 |
Why?
|
| Narcotic Antagonists | 5 | 2017 | 13 | 0.250 |
Why?
|
| Pregnancy | 4 | 2015 | 308 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2021 | 2954 | 0.250 |
Why?
|
| Orthopedics | 1 | 2007 | 77 | 0.250 |
Why?
|
| Interleukins | 1 | 2006 | 21 | 0.250 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 95 | 0.240 |
Why?
|
| Athletic Injuries | 1 | 2006 | 126 | 0.230 |
Why?
|
| Adaptation, Psychological | 4 | 2018 | 164 | 0.220 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 5 | 2006 | 23 | 0.220 |
Why?
|
| Thoracotomy | 1 | 2004 | 29 | 0.220 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2004 | 4 | 0.220 |
Why?
|
| Perioperative Care | 3 | 2018 | 42 | 0.220 |
Why?
|
| Postoperative Period | 5 | 2019 | 238 | 0.220 |
Why?
|
| Acute Kidney Injury | 1 | 2004 | 34 | 0.210 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 161 | 0.210 |
Why?
|
| Insulin | 2 | 2015 | 77 | 0.210 |
Why?
|
| Knee Joint | 3 | 2018 | 566 | 0.200 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2009 | 12 | 0.200 |
Why?
|
| Injections, Intra-Articular | 4 | 2020 | 56 | 0.200 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 1019 | 0.200 |
Why?
|
| Catheterization | 2 | 2015 | 40 | 0.200 |
Why?
|
| Exploratory Behavior | 2 | 2016 | 9 | 0.200 |
Why?
|
| Affect | 3 | 2019 | 57 | 0.200 |
Why?
|
| Adolescent | 4 | 2018 | 1855 | 0.200 |
Why?
|
| Self Report | 3 | 2019 | 192 | 0.190 |
Why?
|
| Analgesia, Obstetrical | 1 | 2002 | 27 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 242 | 0.190 |
Why?
|
| Spinal Puncture | 3 | 2022 | 23 | 0.190 |
Why?
|
| Lidocaine | 4 | 2012 | 20 | 0.190 |
Why?
|
| Headache Disorders | 2 | 2014 | 3 | 0.180 |
Why?
|
| Radiography | 3 | 2015 | 522 | 0.180 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 2 | 2012 | 2 | 0.180 |
Why?
|
| Activities of Daily Living | 4 | 2018 | 355 | 0.180 |
Why?
|
| Telemedicine | 2 | 2020 | 84 | 0.180 |
Why?
|
| Anticonvulsants | 2 | 2012 | 51 | 0.170 |
Why?
|
| Ontario | 1 | 2021 | 11 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 92 | 0.170 |
Why?
|
| Cesarean Section | 2 | 2015 | 26 | 0.170 |
Why?
|
| Up-Regulation | 5 | 2008 | 144 | 0.170 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2010 | 11 | 0.160 |
Why?
|
| Tibial Fractures | 1 | 2020 | 7 | 0.160 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 3657 | 0.160 |
Why?
|
| Anesthesiology | 1 | 2020 | 27 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 189 | 0.160 |
Why?
|
| Incidence | 2 | 2015 | 618 | 0.160 |
Why?
|
| Physicians | 1 | 2021 | 103 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2019 | 6 | 0.150 |
Why?
|
| Hospitals | 1 | 2020 | 155 | 0.150 |
Why?
|
| Illness Behavior | 1 | 2019 | 3 | 0.150 |
Why?
|
| Physician's Role | 1 | 2019 | 14 | 0.150 |
Why?
|
| Endocannabinoids | 1 | 2019 | 3 | 0.150 |
Why?
|
| Uncertainty | 1 | 2019 | 10 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 76 | 0.150 |
Why?
|
| Social Perception | 1 | 2019 | 11 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 79 | 0.150 |
Why?
|
| Oxycodone | 1 | 2019 | 4 | 0.150 |
Why?
|
| Musculoskeletal Pain | 1 | 2019 | 18 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 18 | 0.150 |
Why?
|
| Rodentia | 1 | 2018 | 6 | 0.150 |
Why?
|
| Anesthesia, Spinal | 2 | 2015 | 15 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2009 | 13 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2012 | 314 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 107 | 0.140 |
Why?
|
| Ischemia | 2 | 2017 | 22 | 0.140 |
Why?
|
| Laparoscopy | 1 | 2020 | 182 | 0.140 |
Why?
|
| Betamethasone | 1 | 2018 | 3 | 0.140 |
Why?
|
| Sacroiliac Joint | 1 | 2018 | 6 | 0.140 |
Why?
|
| Triamcinolone Acetonide | 1 | 2018 | 7 | 0.140 |
Why?
|
| Marriage | 1 | 2018 | 5 | 0.140 |
Why?
|
| Affective Symptoms | 1 | 2018 | 11 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2018 | 15 | 0.140 |
Why?
|
| Patient Selection | 3 | 2014 | 167 | 0.140 |
Why?
|
| Triage | 2 | 2020 | 16 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2009 | 26 | 0.140 |
Why?
|
| Arousal | 2 | 2015 | 47 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 145 | 0.140 |
Why?
|
| Amides | 2 | 2010 | 15 | 0.140 |
Why?
|
| Classification | 1 | 2017 | 2 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2017 | 17 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2017 | 24 | 0.130 |
Why?
|
| Knee | 1 | 2017 | 38 | 0.130 |
Why?
|
| beta-Endorphin | 1 | 2017 | 5 | 0.130 |
Why?
|
| Mood Disorders | 1 | 2017 | 23 | 0.130 |
Why?
|
| Wound Closure Techniques | 1 | 2016 | 5 | 0.130 |
Why?
|
| Injections, Epidural | 2 | 2015 | 15 | 0.130 |
Why?
|
| Research Design | 1 | 2018 | 152 | 0.130 |
Why?
|
| Anticipation, Psychological | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cyclooxygenase 1 | 2 | 2008 | 6 | 0.130 |
Why?
|
| Pseudomonas Infections | 1 | 2016 | 32 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 40 | 0.120 |
Why?
|
| Oxygen | 1 | 2016 | 53 | 0.120 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2015 | 1 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 2015 | 3 | 0.120 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 222 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 15 | 0.120 |
Why?
|
| Algorithms | 1 | 2017 | 290 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2015 | 60 | 0.120 |
Why?
|
| Social Behavior | 1 | 2015 | 50 | 0.120 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2015 | 13 | 0.120 |
Why?
|
| Joint Capsule | 1 | 2015 | 35 | 0.120 |
Why?
|
| Age Distribution | 1 | 2015 | 70 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2015 | 64 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2015 | 55 | 0.110 |
Why?
|
| Ibuprofen | 1 | 2015 | 9 | 0.110 |
Why?
|
| Catheters | 1 | 2015 | 15 | 0.110 |
Why?
|
| Infusions, Intravenous | 4 | 2018 | 47 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2015 | 99 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 752 | 0.110 |
Why?
|
| Range of Motion, Articular | 2 | 2009 | 562 | 0.110 |
Why?
|
| Migraine Disorders | 1 | 2014 | 18 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2017 | 241 | 0.110 |
Why?
|
| Pain Clinics | 1 | 2014 | 4 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 557 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 95 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1038 | 0.110 |
Why?
|
| Anesthesia, General | 1 | 2014 | 23 | 0.110 |
Why?
|
| Regression Analysis | 3 | 2019 | 215 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 154 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2004 | 151 | 0.100 |
Why?
|
| Hospitalization | 1 | 2015 | 281 | 0.100 |
Why?
|
| Skin | 2 | 2010 | 119 | 0.100 |
Why?
|
| Exercise | 3 | 2021 | 387 | 0.100 |
Why?
|
| Biomarkers | 3 | 2023 | 455 | 0.090 |
Why?
|
| Phenols | 1 | 2012 | 5 | 0.090 |
Why?
|
| Capsaicin | 1 | 2012 | 8 | 0.090 |
Why?
|
| Perioperative Period | 1 | 2011 | 8 | 0.090 |
Why?
|
| Osteoarthritis, Spine | 1 | 2011 | 5 | 0.090 |
Why?
|
| Interleukin-6 | 2 | 2015 | 68 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2011 | 17 | 0.090 |
Why?
|
| Back Pain | 1 | 2011 | 52 | 0.090 |
Why?
|
| Intracranial Hypotension | 2 | 2008 | 4 | 0.090 |
Why?
|
| Warfarin | 1 | 2011 | 25 | 0.090 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 53 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 12 | 0.090 |
Why?
|
| Biological Availability | 1 | 2010 | 16 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 26 | 0.090 |
Why?
|
| Radioisotopes | 1 | 2010 | 13 | 0.080 |
Why?
|
| Preoperative Period | 1 | 2010 | 62 | 0.080 |
Why?
|
| Diabetic Neuropathies | 1 | 2010 | 10 | 0.080 |
Why?
|
| Peripheral Nerves | 2 | 2014 | 15 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 35 | 0.080 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2011 | 74 | 0.080 |
Why?
|
| Physical Stimulation | 2 | 2013 | 9 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2015 | 323 | 0.080 |
Why?
|
| Epinephrine | 4 | 2012 | 29 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 27 | 0.080 |
Why?
|
| Psychometrics | 1 | 2010 | 175 | 0.080 |
Why?
|
| Neostigmine | 2 | 2007 | 4 | 0.080 |
Why?
|
| Interleukin-18 Receptor alpha Subunit | 1 | 2009 | 1 | 0.080 |
Why?
|
| Interleukin-18 Receptor beta Subunit | 1 | 2009 | 1 | 0.080 |
Why?
|
| Chemokine CCL20 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2009 | 2 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2010 | 59 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2009 | 11 | 0.080 |
Why?
|
| Drug Synergism | 3 | 2004 | 38 | 0.080 |
Why?
|
| Cartilage, Articular | 1 | 2011 | 265 | 0.070 |
Why?
|
| Posterior Horn Cells | 1 | 2008 | 3 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2009 | 90 | 0.070 |
Why?
|
| Depression | 3 | 2019 | 368 | 0.070 |
Why?
|
| Recurrence | 1 | 2008 | 270 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 123 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 31 | 0.070 |
Why?
|
| Postoperative Nausea and Vomiting | 2 | 2006 | 16 | 0.070 |
Why?
|
| Pain, Intractable | 1 | 2007 | 9 | 0.070 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 18 | 0.070 |
Why?
|
| Terrorism | 1 | 2007 | 9 | 0.070 |
Why?
|
| Microglia | 1 | 2008 | 108 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2007 | 35 | 0.070 |
Why?
|
| Neuronal Plasticity | 1 | 2007 | 38 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 1403 | 0.070 |
Why?
|
| Reoperation | 1 | 2010 | 742 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2006 | 45 | 0.060 |
Why?
|
| Europe | 2 | 2017 | 48 | 0.060 |
Why?
|
| Intraoperative Period | 1 | 2006 | 22 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2007 | 163 | 0.060 |
Why?
|
| Indans | 2 | 2004 | 5 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2018 | 64 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2006 | 14 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 46 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2006 | 22 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2006 | 58 | 0.060 |
Why?
|
| Arthroplasty, Replacement | 1 | 2007 | 121 | 0.060 |
Why?
|
| Cauda Equina | 1 | 2005 | 5 | 0.060 |
Why?
|
| Arachnoiditis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Sex Factors | 3 | 2014 | 380 | 0.060 |
Why?
|
| Peripheral Nerve Injuries | 2 | 2015 | 14 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2004 | 5 | 0.060 |
Why?
|
| Cold Temperature | 1 | 2004 | 27 | 0.060 |
Why?
|
| Ribs | 1 | 2004 | 11 | 0.060 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2014 | 17 | 0.050 |
Why?
|
| Weight Gain | 1 | 2004 | 59 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2006 | 537 | 0.050 |
Why?
|
| Nonprescription Drugs | 1 | 2004 | 1 | 0.050 |
Why?
|
| Herb-Drug Interactions | 1 | 2004 | 1 | 0.050 |
Why?
|
| Mediastinal Neoplasms | 1 | 2004 | 9 | 0.050 |
Why?
|
| Plant Preparations | 1 | 2004 | 7 | 0.050 |
Why?
|
| Social Support | 2 | 2015 | 174 | 0.050 |
Why?
|
| Dyssomnias | 1 | 2003 | 5 | 0.050 |
Why?
|
| Neurosurgery | 2 | 2014 | 32 | 0.050 |
Why?
|
| Hydrocodone | 1 | 2023 | 4 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 53 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 5 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 19 | 0.050 |
Why?
|
| Fetal Monitoring | 1 | 2002 | 3 | 0.050 |
Why?
|
| Heart Rate, Fetal | 1 | 2002 | 5 | 0.050 |
Why?
|
| Pruritus | 1 | 2002 | 10 | 0.050 |
Why?
|
| Ion Channels | 1 | 2004 | 203 | 0.050 |
Why?
|
| Intracranial Pressure | 1 | 2002 | 10 | 0.050 |
Why?
|
| Heart Rate | 1 | 2002 | 104 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2002 | 165 | 0.040 |
Why?
|
| Trigger Points | 1 | 2020 | 1 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 7 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 574 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 10 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 11 | 0.040 |
Why?
|
| Military Medicine | 1 | 2020 | 8 | 0.040 |
Why?
|
| Disinfection | 1 | 2020 | 11 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 15 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 35 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 34 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 45 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 375 | 0.040 |
Why?
|
| Radio Waves | 1 | 2020 | 5 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2019 | 5 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 83 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 66 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 302 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 152 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2014 | 218 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 198 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 77 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 578 | 0.040 |
Why?
|
| Anxiety | 1 | 2019 | 143 | 0.040 |
Why?
|
| Medical Records | 1 | 2018 | 28 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 21 | 0.030 |
Why?
|
| Thigh | 1 | 2017 | 26 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 32 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 3 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 2017 | 5 | 0.030 |
Why?
|
| Pain Perception | 1 | 2017 | 5 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2017 | 17 | 0.030 |
Why?
|
| Rest | 1 | 2017 | 27 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 265 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2017 | 85 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 311 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 3 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 19 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2015 | 13 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2015 | 30 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 5 | 0.030 |
Why?
|
| Streptozocin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Empathy | 1 | 2015 | 32 | 0.030 |
Why?
|
| Walking | 1 | 2017 | 233 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 72 | 0.030 |
Why?
|
| Dissection | 1 | 2015 | 19 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2015 | 58 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 153 | 0.030 |
Why?
|
| North America | 1 | 2015 | 31 | 0.030 |
Why?
|
| Internationality | 1 | 2015 | 17 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 64 | 0.030 |
Why?
|
| Flatulence | 1 | 2015 | 1 | 0.030 |
Why?
|
| Optogenetics | 1 | 2014 | 1 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2014 | 6 | 0.030 |
Why?
|
| Neuronavigation | 1 | 2014 | 3 | 0.030 |
Why?
|
| Facial Pain | 1 | 2014 | 7 | 0.030 |
Why?
|
| Wound Infection | 1 | 2014 | 6 | 0.030 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2014 | 8 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 2014 | 16 | 0.030 |
Why?
|
| Hematoma | 1 | 2014 | 17 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 36 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 36 | 0.030 |
Why?
|
| Deep Brain Stimulation | 1 | 2014 | 36 | 0.030 |
Why?
|
| Checklist | 1 | 2014 | 33 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 36 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 105 | 0.030 |
Why?
|
| Diskectomy | 1 | 2016 | 167 | 0.030 |
Why?
|
| Spinal Cord Injuries | 1 | 2014 | 37 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 120 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 103 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2012 | 19 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2014 | 134 | 0.020 |
Why?
|
| Implants, Experimental | 1 | 2012 | 32 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 20 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 281 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 432 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 372 | 0.020 |
Why?
|
| Adrenergic Agonists | 1 | 2010 | 4 | 0.020 |
Why?
|
| Sensation | 1 | 2010 | 11 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 34 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 2010 | 3 | 0.020 |
Why?
|
| Absorption | 1 | 2010 | 3 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 18 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 15 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 32 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 719 | 0.020 |
Why?
|
| Information Management | 1 | 2009 | 1 | 0.020 |
Why?
|
| Program Development | 1 | 2009 | 44 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2009 | 29 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 431 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 79 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2010 | 300 | 0.020 |
Why?
|
| Internet | 1 | 2009 | 78 | 0.020 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2007 | 7 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 43 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 333 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 6 | 0.020 |
Why?
|
| Isoflurane | 1 | 2006 | 7 | 0.020 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2006 | 9 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2007 | 163 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2006 | 33 | 0.020 |
Why?
|
| Vocalization, Animal | 1 | 2005 | 3 | 0.010 |
Why?
|
| Tissue Adhesions | 1 | 2005 | 9 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2005 | 51 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2004 | 1 | 0.010 |
Why?
|
| Colforsin | 1 | 2004 | 12 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 24 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 847 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 150 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2007 | 218 | 0.010 |
Why?
|
| Acetates | 1 | 2003 | 16 | 0.010 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2003 | 12 | 0.010 |
Why?
|
| Foot | 1 | 2003 | 40 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 21 | 0.010 |
Why?
|
| Cisterna Magna | 1 | 2002 | 4 | 0.010 |
Why?
|